Paraguay's Tirzepatide Trade Sparks Fraud Lawsuit and Smuggling Surge

An American entrepreneur has filed a criminal complaint in Ciudad del Este, Paraguay, accusing the local pharmaceutical firm Indufar C.I.S.A. of fraud, breach of trust and criminal conspiracy. The dispute centers on tirzepatide, the active ingredient in the weight‑loss drug Mounjaro, which the U.S.‑owned Bem Estar Distribuidora S.A. was developing as a generic in Paraguay. The entrepreneur alleges that confidential technical and commercial information was misused, leading to an estimated loss of more than $4 million, an 80 % revenue drop and over 20,000 unsold units.

At the same time, Ciudad del Este has become a hub for the illicit trade of tirzepatide into Brazil. Brazilian customs have seized ten times more vials in 2026 than in 2025, and a bank estimate puts the black‑market revenue at $485 million. Paraguayan police report multiple highway robberies targeting trucks carrying the drug, and pharmacy owners, represented by Gerardo Rivalora, say they live in fear of violent assaults. While Brazilian Federal Police have not confirmed organized‑crime involvement, the surge in seizures and robberies highlights growing security challenges on the tri‑border region.